Grant of Share Options

RNS Number : 3417Z

IXICO plc

14 September 2022

 

14 September 2022

IXICO plc

("IXICO" or the "Company")

Grant of Share Options

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience , today announces that it has granted 600,000 options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan').  These options have been awarded across twenty-four employees within the Company and will be exercisable at a price of 29.3p (being at a 25% discount to the closing middle market price per ordinary share on 13 September 2022).

The options are subject to performance conditions linked to revenues and retention within the Company across three years.  No PDMR has received options under this award.

The Company's Remuneration Committee has also reviewed the performance conditions of the December 2019 and July 2020 LTIPs and, acting within the share option scheme rules, amended the review of performance conditions to be annually on the anniversary of each LTIP award. The vesting condition of 50% of the respective award vesting on the third anniversary of the award, with the remaining 50% of the respective award vesting on the fourth anniversary of the award will remain.

For further information please contact:

IXICO plc
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer	[phone]
Cenkos Securities PLC (Nominated adviser and sole broker)		[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. 

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients .

More information is available on www.IXICO.com

 

END

 

 

MSCUOSNRUNUKAAR